Cost-Effectiveness Analysis of Enfortumab Vedotin plus Pembrolizumab as First-Line Treatment for Advanced Urothelial Carcinoma

Saved in:
Bibliographic Details
Published inAdvances in clinical medicine Vol. 15; no. 4; pp. 2151 - 2161
Main Author 谢, 雨璇
Format Journal Article
LanguageEnglish
Published 2025
Online AccessGet full text
ISSN2161-8712
2161-8720
DOI10.12677/acm.2025.1541165

Cover

More Information
ISSN:2161-8712
2161-8720
DOI:10.12677/acm.2025.1541165